Head to Head Comparison: Capstone Therapeutics (NASDAQ:CAPS) & Ryerson (NYSE:RYZ)

Ryerson (NYSE:RYZ) and Capstone Therapeutics (NASDAQ:CAPS) are both small-cap industrials companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.

Institutional and Insider Ownership

94.8% of Ryerson shares are owned by institutional investors. Comparatively, 2.5% of Capstone Therapeutics shares are owned by institutional investors. 6.6% of Ryerson shares are owned by insiders. Comparatively, 39.3% of Capstone Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Ryerson and Capstone Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ryerson	-0.56%	-0.62%	-0.21%
Capstone Therapeutics	-36.51%	-144.43%	-40.48%

Analyst Recommendations

This is a breakdown of current ratings and price targets for Ryerson and Capstone Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ryerson	1	2	0	0	1.67
Capstone Therapeutics	1	0	0	0	1.00

Risk and Volatility

Ryerson has a beta of 1.57, meaning that its share price is 57% more volatile than the S&P 500. Comparatively, Capstone Therapeutics has a beta of -1.5, meaning that its share price is 250% less volatile than the S&P 500.

Valuation & Earnings

This table compares Ryerson and Capstone Therapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ryerson	$4.57 billion	0.29	-$56.40 million	($1.24)	-20.44
Capstone Therapeutics	$48.11 million	0.08	-$21.23 million	($3.35)	-0.05

Capstone Therapeutics has lower revenue, but higher earnings than Ryerson. Ryerson is trading at a lower price-to-earnings ratio than Capstone Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Ryerson beats Capstone Therapeutics on 9 of the 12 factors compared between the two stocks.

About Ryerson

Ryerson Holding Corporation, together with its subsidiaries, processes and distributes industrial metals in the United States, Canada, Mexico, and China. It offers a line of products in carbon steel, stainless steel, alloy steels, and aluminum, as well as nickel and red metals in various shapes and forms, including coils, sheets, rounds, hexagons, square and flat bars, plates, structural, and tubing. The company also provides various processing services, such as bending, beveling, blanking, blasting, burning, cutting-to-length, drilling, embossing, flattening, forming, grinding, laser cutting, machining, notching, painting, perforating, polishing, punching, rolling, sawing, scribing, shearing, slitting, stamping, tapping, threading, welding, or other techniques to process materials. It serves various industries, including commercial ground transportation, metal fabrication and machine shops, industrial machinery and equipment manufacturing, consumer durable equipment, HVAC manufacturing, construction equipment manufacturing, food processing and agricultural equipment manufacturing, and oil and gas. The company was founded in 1842 and is headquartered in Chicago, Illinois.

About Capstone Therapeutics

Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.